Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118629 | 0.94 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA3IDO1 | |
| SCHEMBL7141999 | 0.88 | IDO1 (0.51) | GABRG2GABRB3GABRA5GABRA3IDO1 | |
| SCHEMBL27544569 | 0.84 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA3IDO1 | |
| SCHEMBL7810052 | 0.82 | IDO1 (0.46) | GABRG2GABRB3GABRA5GABRA3IDO1 | |
| SCHEMBL4971912 | 0.80 | GABRG2 (0.41) | GABRG2GABRB3GABRA5GABRA3NPY5R | |
| SCHEMBL7809837 | 0.79 | PTGDR (0.48) | IDO1CLK4MEN1KMT2A | |
| SCHEMBL7141855 | 0.79 | KDM4E (0.45) | NPY5RMEN1KMT2AALDH1A3 | |
| SCHEMBL26110507 | 0.79 | KDM4E (0.45) | NPY5RMEN1KMT2AALDH1A3 | |
| SCHEMBL26463821 | 0.78 | KDM4E (0.44) | NPY5RCLK4MEN1KMT2ACDC7 | |
| SCHEMBL15029205 | 0.78 | MAPK1 (0.42) | CLK4MEN1KMT2ACDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | disclosed |